Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
about
Topical lidocaine for neuropathic pain in adultsLong-term opioid management for chronic noncancer painAnti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safetyPatterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort studyValidation of the Rheumatoid and Arthritis Outcome Score (RAOS) for the lower extremitySerum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanerceptDermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesHow useful are systematic reviews for informing palliative care practice? Survey of 25 Cochrane systematic reviews.Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries.Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice.Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practiceLarge-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review.The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritisFcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterLow-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year periodDrug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.Infliximab: 12 years of experienceTNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern SwedenInfliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefitPerformance of health status measures with a pen based personal digital assistant.Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept.Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.Response criteria for rheumatoid arthritis in clinical practice: how useful are they?Treatment continuation in patients receiving biological agents or conventional DMARD therapy.Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritisPredictors of infusion reactions during infliximab treatment in patients with arthritis.Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern SwedenEvidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease
P2860
Q24194814-DD2C8F40-73AA-4C8B-8F48-F5E7362F2838Q24240811-143B50AE-A3F7-456A-8BDE-200F85220CADQ24673716-BBE8E6FD-7BDE-460E-BEE3-8D50B643FFFEQ24791246-C1FD2A96-9204-4A12-9E54-81A157679C0CQ24798133-46248FE7-4849-456F-A756-C7A275958B9FQ24804764-40D5735E-3B83-4A14-9074-5AA11CDB931DQ24816844-8AE923E4-5D02-437A-82F5-64A9F42C21DDQ26778600-FA16D672-CFFC-4573-BDE0-FAC4B30CDDA9Q30483437-EB9086DD-2A23-4E69-BE56-78087023CC9DQ30885007-23F78083-6576-4EA8-A4D0-0AA7A7A51C38Q30891297-0F9E4715-1FCB-4FF9-8CE3-C08E89F2270CQ33369142-F826D9E3-1133-4673-9487-D90F85850DFDQ33566361-609FD337-B11F-474E-99E7-21FB7C379A0FQ33858767-94B0DA63-6B3E-4B2A-AA06-A6BE309685C8Q33892790-A1CF8642-7FA1-41BC-8E96-BAB929A35D92Q34027648-E0CBDC96-E6B0-401C-98C0-76131E55F25BQ34183220-90160EFD-2836-49E0-8A3F-7E03FBBE34F5Q34208252-273CA903-B2C3-4A3C-82E8-1456AFF64547Q34248283-C44C474B-CB10-4BE7-AC64-7723334CB190Q34462584-01E1A0FE-C0D8-48B6-9CBF-588EEAB39E41Q34623922-6DE56483-F9CB-40F3-ABC7-445D087BED8AQ34654104-96526185-23C1-4045-B15D-4438DA751BECQ34896269-8F59C3EA-9827-4B05-8D6D-461CF22BD5E7Q35048347-208D88E4-67B9-4584-A7CF-DAF8E7A5D197Q35070446-024B8058-74CA-42B1-9B7D-1F199ABDD439Q35553191-A4A334B8-6A10-42B6-A313-22E9B59B749DQ35553775-5F4B6C22-A89E-4AFA-B578-323733989216Q35554807-FD2C0DC2-E86C-44C7-A1C7-A82F3F332A0FQ35555131-492B3763-1718-4032-918F-279E7AE17C27Q35555376-D43F3CA0-34D8-4ABC-BF1C-4E23BAA2FEBBQ35555527-F53D5D0B-CA89-4D4E-8C0F-66A775C7A079Q35555937-51460E89-862C-480A-A220-3095FA21B4E1Q35556040-5ED159D7-CDA4-4169-A5BC-33D1342B6457Q35579309-5898EBEC-BEED-428C-A48E-63CD892BACFFQ35581451-85567E79-8115-46E6-A778-FFE98FDC7EB0Q35605532-86DE7C0B-1927-41D6-8825-5D3092E06F0BQ35605643-49FC5A1C-890F-4187-B707-93EA4351A510Q35630063-0424AB42-FBA4-450A-8A2C-A9F2B63CECFDQ35637221-984EDF83-18E2-46AB-A3F1-8ABD2DECEAF9Q35739971-C77CC10C-946E-4665-8C9E-9F1658635CF3
P2860
Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Etanercept, infliximab, and le ...... programme in southern Sweden.
@ast
Etanercept, infliximab, and le ...... programme in southern Sweden.
@en
type
label
Etanercept, infliximab, and le ...... programme in southern Sweden.
@ast
Etanercept, infliximab, and le ...... programme in southern Sweden.
@en
prefLabel
Etanercept, infliximab, and le ...... programme in southern Sweden.
@ast
Etanercept, infliximab, and le ...... programme in southern Sweden.
@en
P2093
P2860
P356
P1476
Etanercept, infliximab, and le ...... p programme in southern Sweden
@en
P2093
South Swedish Arthritis Treatment Group
P2860
P304
P356
10.1136/ARD.61.9.793
P407
P577
2002-09-01T00:00:00Z